People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Talphera, Inc. | — | Pharmaceuticals | Series B | $97.4M | $74.2M | 2011 |
| Celladon Corp | — | Biotechnology | Series B | $70.9M | $119.1M | 2016 |
| Cerimon Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $3.7M | $8.9M | 2009 |
James H. Welch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James H. Welch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asish Xavier | 1 | 18 |
| Mark Wan | 1 | 10 |
| Stephen Hoffman | 1 | 7 |
| Ansbert Gadicke | 1 | 7 |
| Robert Adelman | 1 | 5 |
| Guy Nohra | 1 | 5 |
| Edgar G Engleman | 1 | 5 |
| Howard Rosen | 1 | 5 |
| Mark Edwards | 1 | 4 |
| Anthony B. Evnin | 1 | 4 |
| James Welch | 1 | 4 |
| Howard B. Rosen | 1 | 4 |
| Nina S. Kjellson | 1 | 4 |
| Vaughn Kailian | 1 | 3 |
| Krisztina Zsebo | 1 | 3 |
| Marina Bozilenko | 1 | 3 |
| Andrew E. Senyei | 1 | 3 |
| Richard King | 1 | 3 |
| Vincent J. Angotti | 1 | 2 |
| Asish R. Xavier | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.